Real‐World Efficacy of Extending Duration of Letermovir Prophylaxis for Allogeneic Stem Cell Recipients
Despite the efficacy of letermovir in preventing csCMVi during immunosuppression, the occurrence of csCMVi following letermovir cessation was still a clinical concern.
Authors
- Takashi Toya (ORCID: https://orcid.org/0000-0002-7436-972X)
- Yasutaka Masuda
- Kairi Kojo
- Atsushi Jinguji
- Chika Kato
- Yukie Terasaki
- Ryoji Yamakawa (ORCID: https://orcid.org/0000-0001-7593-9467)
- Yuho Najima (ORCID: https://orcid.org/0000-0001-8910-0021)
- Noriko Doki
- Masashi Shimabukuro (ORCID: https://orcid.org/0000-0003-4882-9873)
- Fumihiko Ouchi
- Yasutaka Sadaga
- Hiroaki Shimizu (ORCID: https://orcid.org/0000-0001-7484-7405)
- Kaori Kondo
- Kana Kato
- Hiroki Hatsusawa
Institutions
- Tokyo Metropolitan Komagome Hospital (JP)
- Dokkyo Medical University (JP)
Publication Details
- Journal
- Transplant Infectious Disease
- Published
- 2025-10-14
- DOI
- https://doi.org/10.1111/tid.70116
- Citations
- 1
- Primary Topic
- Cytomegalovirus and herpesvirus research
- Type
- article
- Field-Weighted Citation Impact
- 1.35